Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.

John B BuseAnders L CarlsonMitsuhisa KomatsuOfri MosenzonLudger RoseBo LiangKristine BuchholtzHiroshi HorioTakashi Kadowaki

Published in: Diabetes, obesity & metabolism (2018)

Mealtime and post-meal faster aspart in conjunction with insulin degludec provided effective glycaemic control compared with IAsp, with no increased safety risk. Mealtime faster aspart provided PPG control superior to that of IAsp.

Keyphrases

type diabetes
glycemic control
clinical trial
cardiovascular disease
phase iii
randomized controlled trial
placebo controlled